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In both normal and pathological states, cells respond rapidly to
environmental cues by synthesizing new proteins. The selective
identification of a newly synthesized proteome has been hindered
by the basic fact that all proteins, new and old, share the same pool
of amino acids and thus are chemically indistinguishable. We
describe here a technology, based on the cotranslational introduc-
tion of azide groups into proteins and the chemoselective tagging
of azide-labeled proteins with an alkyne affinity tag, to separate
and identify, specifically, the newly synthesized proteins in mam-
malian cells. Incorporation of the azide-bearing amino acid
azidohomoalanine is unbiased, not toxic, and does not increase
protein degradation. As a first demonstration of the method, we
report the selective purification and identification of 195 metabol-
ically labeled proteins with multidimensional liquid chromatogra-
phy in-line with tandem MS. Furthermore, in combination with
leucine-based mass tagging, candidates were immediately vali-
dated as newly synthesized proteins. The identified proteins,
synthesized in a 2-h window, possess a broad range of biochemical
properties and span most functional gene ontology categories.
This technology makes it possible to address the temporal and
spatial characteristics of newly synthesized proteomes in any cell
type.
chemical reporter  protein synthesis  proteomics
The proteome is a dynamic entity, tightly regulated by proteinsynthesis and degradation to maintain homeostasis in cells,
tissues, and organisms. Many biological processes, including cell
growth, differentiation, metabolism, and even learning and
memory, are regulated by translational control of protein syn-
thesis. mRNA expression data from a variety of systems indicate
that the transcriptome responds dynamically to different cellular
states, but because of an independent layer of translational
regulation, the relationship between transcriptome and pro-
teome is not generally predictable.
Differential proteomic approaches have been developed to
compare the protein expression profiles of cells in different
states; such methods include differential 2D gel electrophoresis
(1, 2), isotope-coded affinity tags (3) or isobaric tags for relative
and absolute quantification (4), quantitative proteomic analysis
using samples from cells grown in 14N or 15N media (5, 6), and
stable isotope labeling by amino acids in cell culture (7, 8). These
methods have successfully elucidated complex processes such as
nuclear protein dynamics (7, 9), responses to cytokines (10), and
mechanisms of neurodegenerative diseases (11, 12), as well as
promoting biomarker discovery (13–15). More recently, ap-
proaches focusing on posttranslational modifications have
emerged to specifically explore the ‘‘phosphoproteome’’ (16–18)
and ‘‘glycoproteome’’ (19–22) of a cell. Additionally, the con-
stituents of protein complexes can be determined by means of
tandem affinity purification of tagged cellular proteins followed
by MS analysis (23).
Studies of proteome dynamics would be facilitated by methods
that enable separation of newly synthesized proteins from the
preexisting protein pool. Enrichment of newly synthesized pro-
teins has two advantages: (i) it permits an analysis of the primary
protein synthesis response to internal and external cues, and (ii)
it decreases the complexity of the sample, potentially enabling
the identification of proteins expressed at low levels.
In recent years, small bioorthogonal functional groups, most
notably azides and ketones, have been exploited to tag proteins
(24–27), glycans (28–31), and lipids (32) in cells. These groups
are incorporated by the cell’s own biosynthetic machinery; the
subsequent ligation with reactive probes allows their detection
(for a recent review, see ref. 33). The selective chemistry of the
azide group has proven especially useful in the labeling of
proteins (34–36) and cell surface glycans (37). Here we describe
the use of azidohomoalanine (AHA) to tag newly synthesized
proteins in mammalian cells. Tagged proteins are then separated
from the preexisting proteome by affinity purification and
subjected to identification by tandem MS. We demonstrate the
power of the method, which we call bioorthogonal noncanonical
amino acid tagging (BONCAT), by identifying 195 proteins
synthesized in a 2-h time window in human embryonic kidney
(HEK)293 cells.
Results
Metabolic Labeling of Newly Synthesized Proteins with AHA. To
assess the suitability of AHA for labeling newly synthesized
proteins in mammalian cells, we first examined its potential
toxicity in a mammalian cell line and in neurons. Incubation
with methionine was used as a control, because AHA serves
as a surrogate for methionine. After 2 h, propidium iodide
staining revealed no differences in cell viability between AHA-
and methionine-treated cells (Fig. 1A). We also examined
toxicity in a less robust and more fragile mammalian cell type,
primary cultured postnatal neurons. Hippocampal neurons
were infected with a destabilized and myristoylated form of the
f luorescent protein GFP (38) to visualize their morphology
and incubated for 2 h with either AHA or methionine. We
found that AHA was not toxic to neurons, as indicated by
healthy neuronal processes and the absence of abnormal
varicosities in the dendrites (Fig. 1B).
To determine whether AHA is incorporated into mammalian
proteins, we tagged lysates prepared from AHA-treated
HEK293 cells with the alkyne linker biotin-PEO-propargylam-
ide (26). SubsequentWestern blot analysis with a biotin antibody
revealed the successful incorporation of AHA into a wide variety
of cellular proteins (Fig. 2A). To determine the specificity of
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AHA incorporation into newly synthesized proteins, we added
the protein synthesis inhibitors anisomycin and cycloheximide to
HEK293 cultures along with AHA. Although abundant signal
was detected in cells treated with AHA, no signal was detected
in either the methionine or the protein synthesis inhibitor lanes
of the Western blot (Fig. 2A), confirming that this procedure
labels newly synthesized proteins with high specificity. Further-
more, metabolic colabeling with [35S]cysteine revealed no dif-
ferences in the total radioactive signal intensity or changes in the
migration pattern of total protein samples from AHA- vs.
methionine-labeled HEK293 cells after 2 h of labeling with the
amino acids (Fig. 2B and Fig. 5A, which is published as sup-
porting information on the PNAS web site). Thus there is no
evidence that AHA exposure alters global protein synthesis rates
under the conditions used here.
Next, we examined whether AHA might promote or alter the
ubiquitin-mediated degradation of preexisting and newly syn-
thesized proteins. To examine the ubiquitination of newly
synthesized proteins, we compared the population of newly
synthesized and ubiquitinated proteins in AHA and methionine-
treated cells. HEK293 cells were incubated for 2 h with [35S]cys-
teine and AHA or methionine in the presence of a proteasome
inhibitor to inhibit the degradation of ubiquitinated species. No
increase in radioactive signal or in ubiquitination of newly
synthesized proteins was observed in AHA-treated cells when
compared to buffer or methionine controls (Fig. 3), indicating
that AHA incorporation does not cause severe protein misfold-
ing or degradation when cells are challenged for 2 h. Further-
more, no increase in the ubiquitination of total protein was
observed in AHA-treated cells when compared to buffer or
methionine controls (see Fig. 5 A and B).
Identification of Newly Synthesized Proteins by BONCAT. The BON-
CAT procedure is facilitated by direct proteolysis of affinity-
purified proteins on the matrix, bypassing the need for an elution
step. We therefore designed the alkyne affinity tag 1, which
carries an N-terminal biocytin residue, two trypsin cleavage sites,
a FLAG-antibody epitope, and a C-terminal propargylglycylam-
ide (Fig. 4A). Affinity tag 1 and on-matrix proteolysis were used
in all of the experiments described below. Because sequence
coverage for the majority of proteins identified in shotgun
proteomic approaches such as the multidimensional protein
identification technique, MudPIT (see refs. 39 and 40), is lower
than 40% (41), HEK293 cells were treated with AHA and with
d10-leucine (d10-Leu) to provide an independent marker for
newly synthesized proteins.
Affinity-purified proteins were identified by MudPIT (39, 40).
A set of stringent search constraints including fully tryptic status
of each peptide (42); a minimum of two valid peptides per locus;
minimum crosscorrelation coefficients of 1.8, 2.5, and 3.5 for
singly, doubly, and triply charged ions, respectively; and a
minimum of one peptide containing an AHA-derived or d10-Leu
modification were required to ensure that identified proteins
were translated during the AHA-labeling step. After perfect tag
cleavage, the mass gain of tagged AHA over methionine is 107
atomic mass units. In the case of imperfect tag cleavage, the
resulting mass gain of tagged AHA over methionine would be
Fig. 1. AHA is not toxic to mammalian cells. (A) HEK293 cells were incubated
for 2 h with HBS, 4 mM methionine in HBS, or 4 mM AHA in HBS and then
incubated with propidium iodide (PI) to stain for dead cells. Shown are
Nomarski (Upper) and PI (Lower) signals. (Scale bar 100 m.) (B) Dissociated
hippocampal cultured neurons (12 days in vitro) infected with a destabilized
and myristoylated variant of GFP were incubated for 2 h with equimolar
concentrations of AHA or methionine. Images show representative neurons
expressing the GFP reporter indicating no change in the gross morphology of
AHA-treated neurons compared to methionine controls. Arrows indicate
dendrites, and arrowheads point to somata. (Scale bar, 50 m.)
Fig. 2. Protein synthesis-dependent incorporation of AHA and analysis of
global protein synthesis levels in the presence of AHA. (A) Western blot
analysis for biotinylated AHA-labeled proteins in cell lysates from HEK293 cells
incubated with AHA in the absence or presence of the protein synthesis
inhibitors anisomycin or cycloheximide as compared to methionine control.
Biotin immunoreactivity depends completely on protein synthesis and the
presence of the AHA. (B) Line scan of radioactivity-labeled newly synthesized
proteins transferred onto a nitrocellulose membrane from cells treated with
AHA (black line) or methionine (red line) for 2 h.








695.6 atomicmass units (with no further fragmentation of the tag
moiety required), whereas in the event of failed tagging (unli-
gated AHA) the mass loss of AHA over methionine would be 5.1
atomic mass units. A detailed list of all SEQUEST and DTASELECT
(The Scripps Research Institute) search constraints can be found
in Supporting Text, which is published as supporting information
on the PNAS web site. Four independent experiments were run.
To test our ability to detect newly synthesized proteins, we
examined AHA incorporation in the endogenous proteome of
HEK293 cells. In addition, we transiently expressed a hemag-
glutinin- (HA) tagged version of the brain-specific (43, 44)
mammalian huntingtin-associated protein 1A (HAP1A) in
HEK293 cells. Proteins were purified from HEK293 cells ex-
pressing HA-HAP1A treated with either AHA or methionine
for 2 h. Although abundant biotin signal was detected in lysates
prepared from AHA-treated cells, negligible biotin signal was
detected in the lysates prepared from methionine-treated cells
(Fig. 4B). In addition, HA-HAP1Awas exclusively present in the
Neutravidin affinity matrix bound fraction of AHA-treated
lysates (Fig. 4B) and absent after trypsination. Given that
HA-HAP1A contains 14 methionine residues, a complete ex-
change of methionine with tagged AHA would lead to a mass
gain of 23 kDa. We observed tagged HA-HAP1A migrating as
a ‘‘smear’’ 7 kDa higher than untagged HA-HAP1A, indicat-
ing successful incorporation and tagging of up to four AHA
residues. This incomplete exchange of methionine fits with the
observation of decreased efficiency of AHA activation by me-
thionyl-tRNA synthetases made by Kiick et al. (45).
As expected, 11 different valid peptides for HA-HAP1A
(27.3% sequence coverage) were identified in four AHA MS
experiments (Fig. 6, which is published as supporting informa-
tion on the PNAS web site online), but no single peptide was
recovered in control samples treated with methionine. Repre-
sentative fragmentation spectra for HA-HAP1A peptides with-
out modifications, with several d10-Leu substitutions, or with an
AHA substitution show that modifications can be reliably de-
tected using AHAd10-Leu mass tagging (Fig. 6). Six identified
peptides contained at least one modification due to either an
AHA-derived or a d10-Leu modification. This suggests that the
combination of affinity purification of alkyne-tagged AHA-
labeled proteins and d10-Leu mass tagging allows secure valida-
tion of newly synthesized proteins.
We next explored the identity and representation of all
HEK293 cell proteins synthesized in a 2-h time window. A total
of 195 unique proteins were identified in AHA samples (Table
Fig. 3. Newly synthesized AHA-labeled proteins are not subject to increased
protein degradation. (A) Autoradiogram analysis of immunoprecipitated ubi-
quitinated newly synthesized proteins of cell extracts from AHA-treated
HEK293 cells as compared to methionine control samples (2-h treatment in the
presence of [35S]cysteine). Quantification of radioactive signals of immuno-
precipitates is shown in the graph. n  11 in four independent experimental
sets. (B) Corresponding Western blot analysis for ubiquitinated proteins of
immunoprecipitates in AHA-treated HEK293 cells as compared to methionine
control samples.
Fig. 4. Purification of AHA-labeled proteins after azide–alkyne ligation with
a biotin-FLAG-alkyne tag. (A) Structure of the trypsin-cleavable biotin-FLAG-
alkyne tag 1. Biotin (red rectangle), alkyne (green rectangle), and the tryptic
cleavage sites (blue scissors) are indicated. The FLAG epitope DYKDDDDK is
separated from the biotin moiety by a short linker (GGA). (B) Western blot
analysis for affinity-purified biotinylated proteins using the biotin-FLAG-
alkyne tag. Cell lysates from both AHA and methionine-treated HEK293 cells
were subjected to [3  2] cycloaddition with the biotin-FLAG-alkyne tag and
subsequently purified by using Neutravidin affinity matrix. Except for the
nonspecific protein staining of samples containing Neutravidin affinity resin
(Neutravidin affinity-matrix bound), control samples show no biotin signal.
Note the higher migration level of alkyne-tagged HA-HAP1A protein (lanes
indicated by asterisks) compared to the untagged protein in the methionine
control and in the supernatant of the AHA sample. Sizes of marker proteins are
indicated. NA, Neutravidin.
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1), with 108 proteins (54.6%) identified in more than one
experiment. In control samples, only two proteins were identi-
fied containing a d10-Leu modification in a single experiment
(Cytokeratin type II and Keratin 9); no single protein was
identified in more than one experiment. One identified protein
was shared by AHA and control samples (splice isoform 1 of
DNA-dependent protein kinase catalytic subunit). The entire list
of the 195 newly synthesized proteins, as well as the list of
nonredundant peptides identified in the four independent ex-
periments, is provided in Tables 2 and 3, which are published as
supporting information on the PNAS web site, respectively. A
Western blot analysis for EF2 and histone proteins confirmed
the identification of newly synthesized proteins as well as their
proper subcellular localization (for histones) in AHA-treated
HEK293 cells with BONCAT (Fig.7, which is published as
supporting information on the PNAS web site).
In all four experiments, a total of 1,028 nonredundant peptides
accounted for the 195 proteins identified using the above-stated
search constraints for SEQUEST and DTASELECT. Of the 1,028
identified peptides, 331 contained at least one modification
(assessed by using a Python script FINDMODDTASELECT) due to
either d10-Leu or AHA, 295 peptides contained at least one
d10-Leu modification, 28 peptides were identified with at least
one unligated AHA residue, and one peptide was identified with
a successfully tagged and perfectly cleaved AHA residue. No
AHA-ligated imperfectly digested peptide was identified. Oxi-
dized methionine was observed in 41 of the peptides, with 10 of
these bearing at least one d10-Leu modification. The majority of
d10-Leu-containing peptides showed a complete exchange of the
deuterated amino acid. Five peptides were identified as a mixed
population of deuterated and native leucine. That the majority
of modified peptides contain a d10-Leu modification is most
likely because of the high abundance of this amino acid in
proteins (9.89% in the database indicated above). The remaining
697 (of 1,028) nonredundant peptides contained neither d10-
Leu-AHA modifications nor an oxidized methionine but are
included in the list because a peptide that contained a d10-Leu
or AHA modification was identified from the same protein.
It is worth noting that 257 additional proteins, which passed
the search constraints of a minimum of two valid peptides per
locus and minimum crosscorrelation coefficients (for values, see
above) but did not pass the AHA or d10-Leu modification
criteria, were identified in AHA-treated samples. One hundred
nine of these nonmodified proteins were also identified in the
methionine-treated samples, among them proteins such as the
natively biotinylated protein pyruvate carboxylase (46) or ker-
atin family proteins; the latter is a common contaminant in MS
experiments. Only 15 proteins without any metabolic modifica-
tions were identified in methionine-treated samples.
To assess the false-positive rate, we modified a protocol devel-
oped by Peng et al. (47). On the single-peptide level, we found three
single false-positive peptide identifications among the AHA sam-
ples (of a total of 2,840 nonredundant peptides) compared with
seven false-positive identifications of a total of 19 peptides for
control samples, when a fully tryptic status (42) and a single
modified peptide were required (Table 4, which is published as
supporting information on the PNAS web site). Note that none of
these false-positive peptides passed our filter criteria requiring a
minimum of two peptides for valid protein identification.
We observed no evident unique features of either of the
modified peptides such as a preference for one ion series over the
other or the in-sequence localization of the modification. Fur-
thermore, we subjected nontrypsinized and trypsinized AHA-
Biotin-Flag-tag fractions to MS analysis, which revealed the
successful identification of all expected fragments, indicating
that the tag can be trypsinized as anticipated, and the remaining
fragments can be detected (data not shown). A reduction in
sample complexity might be beneficial for the future detection
of more modified peptides.
Awide range of biochemical and functional properties (indicated
in Table 2) are represented among the 194 endogenous HEK293
proteins identified in these four experiments. Isoelectric points
ranged from 4.6 (nucleophosmin) to 11.4 (histone H4). In addition,
a wide range ofmolarmasses, from 11 kDa (histoneH4) to 466 kDa
(splice isoform 2 of DNA-dependent protein kinase catalytic sub-
unit) were also represented, showing that BONCAT can detect
proteins with diverse biochemical properties. We examined the 194
candidates for their association to Gene Ontology categories using
the software tool GOMINER (48). Annotations representing the
majority of protein categories were assigned to 162 of the 194
proteins identified (Fig. 8, which is published as supporting infor-
mation on the PNAS web site). Among the identified candidates
were highly expressed housekeeping genes like pyruvate kinaseM2,
 enolase, members of the ribonucleoprotein family for mRNA-
binding (heterogenous nuclear ribonucleoprotein K), or the struc-
tural proteins actin and -tubulin. More importantly, the identifi-
cation of generally lower abundance proteins like transcription and
translation activity regulators (for example SART-1, ribosome
biogenesis protein BOP1, or SWISNF-related matrix associated
actin-dependent regulator of chromatin subfamily A member 5)
demonstrate that our technology possesses sensitivity adequate to
identify proteins of low expression levels. Finally, among the 194
(195 including HA-HAP1A) proteins, we identified soluble cyto-
plasmic proteins (actin or HA-HAP1A), membrane-associated
proteins as well as insoluble proteins, e.g., the endoplasmic retic-
ulumprotein calnexin, the nuclearmatrix proteinmatrin 3, or lamin
B. It is worth noting that the average methionine content of our
candidate proteins is 2.40%, only slightly higher than the methio-
nine content of the whole database (2.13%, determined with a
Python script AAEXCLUDE; Fig. 9, which is published as sup-
porting information on the PNAS web site, provides a graph of
methionine content in human proteins), indicating that BONCAT
does not enrich for proteins high in methionine content. In support
of this, one candidate protein identified, histone H4, possesses only
two methionine residues in its sequence and was yet identified.
Most mammalian proteins are subject to a variety of posttransla-
tional modifications including N-terminal processing by methionyl
aminopeptidases. In the human database used in the present study,
5.08% of all protein sequences (2,538 entries) contain only one
methionine, as the initiating amino acid. TheN-terminal processing
and cleavage of the first (methionine) residue during protein
maturation could prevent identification of these proteins. However,
a recent study (49) has reestimated that N-terminal posttransla-
Table 1. Overview of identified proteins in four independent




Four AHA exp. 30 15.2
Three AHA exp. 23 11.6
Two AHA exp. 55 27.8
One AHA exp. 87 43.9
Two AHA and one Met exp. 1 0.5
One Met exp. 2 1.0
Shown are the numbers and percentages of proteins identified in the four
independent experiments. Listed counts for identified proteins were acquired
under the following criteria: minimum of two valid peptides and one modified
peptide per locus, fully tryptic status required and minimal crosscorrelation
coefficient and DeltCN (normalized difference of crosscorrelation coefficients
between the best sequence and each of the other sequences), as indicated in
Material and Methods. Proteins that are subsets of each other (a subset
protein is one for which all peptides are found in another protein) were
combined and counted as a single identification in the report. exp., experi-
ment(s).








tional processing and acetylation is likely to occur for only 30%,
rather than 80%, of all mammalian proteins. In this context, we
suggest the possibility that AHA can be processed by methionyl
aminopeptidases (see Supporting Text). Finally, we note that 511
ORFs (1.02% of a total of 49,925 ORFs) of the human database do
not contain a single methionine residue and therefore could not
have been detected with BONCAT. These 511 ORFs include
proteins predicted to be 25 residues as well as incomplete
sequences. Taken together, these data indicate that we can enrich
and identify newly synthesized proteins covering a wide range of
biochemical and functional properties after a 2-h window of AHA
incubation.
Concluding Remarks
A thorough understanding of cellular function requires a dynamic
view of the proteome. Temporal resolution is essential if one is to
describe the immediate responses of cells to environmental
changes, rather than responses that may be secondary or tertiary.
Elucidating these immediate changes in the protein composition of
a cell at a given state is a challenge requiring specialized tools,
techniques specific and sensitive enough to specifically detect subtle
changes in proteomic content. Taking a series of ‘‘snapshots’’ of
cellular actions will allow us to capture the temporal dynamics of
these processes. Understanding the temporal dynamics of processes
such as signal transduction initiation and diversificationwill provide
invaluable insights for target recognition, biomarker discovery, and
drug development. Unique to the BONCAT approach are the
selective labeling and enrichment of the subproteome of newly
synthesized proteins, thereby raising the chances of identifying new
proteins made against a bewildering background of preexisting
proteins. Protein labeling using BONCAT is analogous to meta-
bolic labeling with radioactive amino acids such as [35S]cysteine or
[35S]methionine and allows the immediate validation of candidate
proteins using AHA- or d10-Leu-based modifications as identifica-
tion constraints, thereby omitting obligatory and often time-
consuming secondary validation steps. In conjunction with short
incubation times, metabolic labeling with AHA will be particularly
useful for postmitotic cell culture systems. Although stable isotope
labeling by amino acids in cell culture-based approaches has proven
to be very powerful for dividing cell systems for which a complete
incorporation of a given ‘‘light’’ or ‘‘heavy’’ form of an essential
amino acid is desirable, this is not an easy feat in postmitotic cells
(8, 50). In this regard, it is worth noting that labeling of primary
hippocampal neurons with AHA did not appreciably affect their
survival, morphology, or protein synthesis. The BONCAT tech-
nique, combined with subcellular fractionation or microdissection
of tissue (51), could provide a means for the development of a
comprehensive picture of temporal and spatial aspects of cellular
proteomes.
Methods
Reagents. Information on reagents and antibodies used in this
study can be found in Supporting Text.
Cell Culture. HEK293 cells were cultivated in DMEM plus 10%
FCS and penicillinstreptomycin (all from Invitrogen). Dissoci-
ated hippocampal neuron cultures were prepared from newborn
rat pups (P0), as published previously (38). Cell viability assays,
measurement of ubiquitination levels, radioactive metabolic
labeling, transient transfection, and viral infection are described
in Supporting Text.
[3  2] Cycloaddition Chemistry and Purification of Tagged Proteins.
AHA, biotin-PEO-propargylamide, and the triazole ligand were
prepared as described (52–54). The cleavable biotin-FLAG-alkyne
tagwas synthesized by theGenScript Corporation (Piscataway,NJ).
d10-Leu was purchased from Sigma. A time window of 2 h was
chosen for the AHA incubation step to allow for new protein
synthesis to take place without any further manipulation of the cells
such as stimulation or starvation being necessary. Cell pellets,
typically 1.95–2.1 mg of total protein per single purification andMS
analysis, as well as subcellular fractions were lysed in 1% SDS in
PBSPI-E (tagging buffer) with genomic DNA sheared with a
syringe and a needle and boiled for 10 min at 96–100°C. Lysates
were diluted to 0.2% SDS0.2%Triton X-100 in PBS, pH 7.4PI-E
before addition of 200 mM triazole ligand50 mM alkyne tag100
mg/ml copper (I) bromide. The reaction was allowed to proceed for
6 h at room temperature, and excess reagents were removed by gel
filtration through PD-10 columns (Amersham Pharmacia Bio-
science). Optimal concentrations (2.86–4.0 mM) of AHA were
determined bymonitoring the biotin signal strength on theWestern
blot level with no change in the level of ubiquitination of proteins
(data not shown). Protein extracts were adjusted to 1% Nonidet
P-40 (Sigma)0.1% SDS in PBS, pH 7.4PI-E, and tagged proteins
were purified on Immobilized Neutravidin affinity resin (Pierce).
After extensive washing in incubation buffer, followed by washes in
1%Nonidet P-40 in PBS as well as 50 mM ammonium bicarbonate
buffer, resin suspensions were incubated for 10 min at 70°C and
adjusted to 2 M urea as 25–33% slurries. Trypsination was done as
described in ref. 55. In a typical experiment, 400 l of peptide
solution was loaded for MS analysis.
MS and Data Analysis. Analysis of peptide mixtures by MudPIT
was done essentially as described in Graumann et al. (55), using
aHP-1100 quaternary HPLC pump (Agilent, Palo Alto, CA) and
a LCQ-DecaXP electrospray ion trap MS (ThermoElectron,
Palo Alto, CA). Proteolytically digested samples were separated
on a triphasic microcapillary column basically as described in
McDonald and Yates (56). First, samples were loaded onto a
biphasic column (2.5 cm of Aqua C18 reverse-phase material
(Phenomenex, Ventura, CA) placed upstream of 3.5 cm of SCX
resin (Partisphere SCX, Whatman) packed into a 100-m inter-
nal diameter-fused silica column (PolyMicro Technology, Phoe-
nix) fitted into an Inline MicroFilter Assembly unit with a
0.5-m PEEK Frit (all from Upchurch Scientific, Oak Harbor,
WA). After sample loading, a column head packed with 6.5-cm
Aqua C18 resin was attached at the other end of the MicroFilter
Assembly unit, creating a triphasic RP-SCX-RP column. Sample
separation was achieved with a six-step chromatography pro-
gram, and the column eluate was analyzed as described in
Graumann et al. (55). Centroided fragmentation spectra ac-
quired by XCALIBUR 1.3 software (Thermo Electron) were
evaluated for spectrum quality and charge state by using 2TO3
(57) and searched against the translated ORFs of the human IPI
database ipi.HUMAN.v3.06.fasta (www.ebi.ac.ukIPIIPIhelp.
html) by SEQUEST (58), Version 27, Rev. 9, using unified input
and output files (59). Details of relevant SEQUEST parameters,
DTASELECT, and CONTRAST (56, 60) settings, as well as assess-
ment of false-positive rates, can be found in Supporting Text.
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